A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

Under Friday’s final ruling anti-obesity medications for weight-loss will remain ineligible for Medicare coverage.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for Wegovy and Zepbound ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

The Biden administration sought to sidestep this obstacle by issuing a rule in November reinterpreting existing statutes to allow for Medicare Part D to cover anti-obesity drugs. But earlier this ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

On April 4, CMS announced it would not include Medicare Part D coverage ... Part D coverage of anti-obesity medications for Medicare Part D enrollees with obesity where the drug’s prescribed ...